Public Private Partnerships
By 2002, there were over 100 international private-public partnerships, with a combined investment of several billion dollars. New types of organisation are needed to co-ordinate and maximise the benefits of new partnerships. Experience is helping to strengthen the functions of governance, management and performance monitoring, and to ensure transparency.
Public-private partnerships work best with shared objectives and decision making, although each partner's role and benefits will differ. Potential conflict of commercial and public health interest must be minimised, and partnerships need to maximise members' particular skills. Involvement of developing countries, international public sector leadership from agencies such as WHO, and significant investment of public resources are also critical to the success of PPPs.
- Global health: making partnerships work - seven recommendations for building effective global public-private health partnerships
-
This paper explores the effectiveness of global public-private health partnerships (GHPs). The paper argues that global public-private health partnerships add significant value in tackling diseases of poverty but that the value of these partnerships is compromised by a number of common problems.
Recommended readings
- Public-private partnerships for drugs and vaccines: special issue of the Bulletin of the World Health Organization
- ( Bulletin of the World Health Organization : the International Journal of Public Health , 2001)
- This themed edition of the Bulletin of the World Health Organisation presents editorials, research, reviews, discussions, letters and interviews on the issue of public-private partnerships for drugs a...
- Developing successful global health alliances
- ( Bill and Melinda Gates Foundation , 2002)
- Efforts to tackle public health problems in developing countries increasingly rely on international alliances, such as the Global Polio Eradication Initiative. But while there are clear advantages to ...
Latest Additions
- Opportunities for scaling up neglected-disease drug development
- ( Mary Moran / Public Library of Science Medicine , 2005)
- Whereas only 13 new drugs have been developed for neglected tropical diseases since 1975, this paper, published in PLoS Medicine, notes that this is as a result of current perception that these diseas...
Fairly pricing antiretroviral drugs
- ( D. Dionisio;C. Fabbri;D. Messeri / Future Medicine , 2009)
-
Despite progress, antiretroviral therapy coverage in low- and middle-income countries remains poor: only 31% of HIV-infected people in need were receiving treatment in 2007. Obstacles include weak ...
- How can the private sector help access to and quality of reproductive health services?
- ( B. O’Hanlon / Private Sector Partnerships-One , 2009)
- Increasingly, governments and donor agencies recognise the need to engage the private sector to increase the coverage of health services. This policy brief by PSP-One (a USAID funded project) shows ho...
